The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Can Oncotype DX recurrence score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population.
Laura G. Estevez
No relevant relationships to disclose
Isabel Calvo
No relevant relationships to disclose
Maria Fernandez-Abad
No relevant relationships to disclose
Juan Jose Cruz
No relevant relationships to disclose
Ana Suarez
No relevant relationships to disclose
Fernando Lopez-Rios
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose